Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients
Completed
Celgene
Phase 2/Phase 3
2012-09-18
This study is a two-part trial consisting of Part A (presented in this record) and Part B
(see NCT02047734).
The primary objective in Part A of this study was to demonstrate the superior efficacy of
ozanimod compared to placebo by showing a reduction in the cumulative number of total
gadolinium-enhancing (GdE) lesions from Week 12 to Week 24 in patients with relapsing
multiple sclerosis (RMS).
Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
Completed
Celgene
Phase 3
2013-12-03
This study is a two-part trial consisting of Part A (see NCT01628393) and Part B, presented
within this record.
The primary objective of Part B is to assess whether the clinical efficacy of ozanimod
(RPC1063) is superior to interferon beta-1a (IFN β-1a; Avonex®) in reducing the rate of
clinical relapses at the end of Month 24 in patients with relapsing multiple sclerosis (RMS).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
